Although LGR5+-targeting therapies are still largely in their infancy, the analogy with neuroendocrine tumors, which are successfully combated by radioactive somatostatin analogs (e.g., 177Lu-Dotatate) that target receptors with homology to LGR527, suggests that radioactive drugs (e.g., R-spondin) may be explored for developing CSC-targeted therapeutics against liver cancer28. The gene discussed is LGR5; the disease is neuroendocrine neoplasm.